Efficacy of COPE-A for PTSD and SUD in Young People Demonstrated in RCT
The COPE-A treatment showed significantly greater reductions in PTSD symptom severity compared to supportive counseling at 4 months, with effects maintained at 12 months.
Company
Pharmaceutical intelligence for COPE-A with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.